You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Sun Pharma slips in volatile trade

Capital Market 

Industries lost 0.85% to Rs 707.70 at 10:05 on BSE, amid intraday volatility after the company announced the launch of BromSite (bromfenac ophthalmic solution) 0.075% in the US market.

The announcement was made after market hours yesterday, 28 November 2016.

Meanwhile, the S&P Sensex was up 98.85 points or 0.38% at 26,449.02.

On BSE, so far 95,000 shares were traded in the counter as against average daily volume of 3.68 lakh shares in the past one quarter. The stock was volatile. The stock lost as much as 1.06% at the day's low of Rs 706.20 so far during the day. The stock rose as much as 1.14% at the day's high of Rs 721.95 so far during the day. The stock had hit a 52-week high of Rs 898 on 23 February 2016. The stock had hit a 52-week low of Rs 572.40 on 9 November 2016. The stock had outperformed the market over the past one month till 28 November 2016, sliding 4.03% compared with the Sensex's 5.7% fall. The scrip had, however, underperformed the market in past one quarter, declining 5.58% as against the Sensex's 5.15% fall.

The large-cap company has equity capital of Rs 240.68 crore. Face value per share is Rs 1.

A nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery, BromSite will be marketed by Sun Ophthalmics, the company's branded ophthalmic business solution. BromSite is the first branded product launched by the company in the US, following its focus on Specialty business.

On a consolidated basis, Industries' net profit rose 117.3% to Rs 2235.14 crore on 13.2% growth in net sales to Rs 7764.03 crore in Q2 September 2016 over Q2 September 2015.

Industries is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Sun Pharma slips in volatile trade

Sun Pharmaceutical Industries lost 0.85% to Rs 707.70 at 10:05 IST on BSE, amid intraday volatility after the company announced the launch of BromSite (bromfenac ophthalmic solution) 0.075% in the US market.

Industries lost 0.85% to Rs 707.70 at 10:05 on BSE, amid intraday volatility after the company announced the launch of BromSite (bromfenac ophthalmic solution) 0.075% in the US market.

The announcement was made after market hours yesterday, 28 November 2016.

Meanwhile, the S&P Sensex was up 98.85 points or 0.38% at 26,449.02.

On BSE, so far 95,000 shares were traded in the counter as against average daily volume of 3.68 lakh shares in the past one quarter. The stock was volatile. The stock lost as much as 1.06% at the day's low of Rs 706.20 so far during the day. The stock rose as much as 1.14% at the day's high of Rs 721.95 so far during the day. The stock had hit a 52-week high of Rs 898 on 23 February 2016. The stock had hit a 52-week low of Rs 572.40 on 9 November 2016. The stock had outperformed the market over the past one month till 28 November 2016, sliding 4.03% compared with the Sensex's 5.7% fall. The scrip had, however, underperformed the market in past one quarter, declining 5.58% as against the Sensex's 5.15% fall.

The large-cap company has equity capital of Rs 240.68 crore. Face value per share is Rs 1.

A nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery, BromSite will be marketed by Sun Ophthalmics, the company's branded ophthalmic business solution. BromSite is the first branded product launched by the company in the US, following its focus on Specialty business.

On a consolidated basis, Industries' net profit rose 117.3% to Rs 2235.14 crore on 13.2% growth in net sales to Rs 7764.03 crore in Q2 September 2016 over Q2 September 2015.

Industries is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Sun Pharma slips in volatile trade

Industries lost 0.85% to Rs 707.70 at 10:05 on BSE, amid intraday volatility after the company announced the launch of BromSite (bromfenac ophthalmic solution) 0.075% in the US market.

The announcement was made after market hours yesterday, 28 November 2016.

Meanwhile, the S&P Sensex was up 98.85 points or 0.38% at 26,449.02.

On BSE, so far 95,000 shares were traded in the counter as against average daily volume of 3.68 lakh shares in the past one quarter. The stock was volatile. The stock lost as much as 1.06% at the day's low of Rs 706.20 so far during the day. The stock rose as much as 1.14% at the day's high of Rs 721.95 so far during the day. The stock had hit a 52-week high of Rs 898 on 23 February 2016. The stock had hit a 52-week low of Rs 572.40 on 9 November 2016. The stock had outperformed the market over the past one month till 28 November 2016, sliding 4.03% compared with the Sensex's 5.7% fall. The scrip had, however, underperformed the market in past one quarter, declining 5.58% as against the Sensex's 5.15% fall.

The large-cap company has equity capital of Rs 240.68 crore. Face value per share is Rs 1.

A nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery, BromSite will be marketed by Sun Ophthalmics, the company's branded ophthalmic business solution. BromSite is the first branded product launched by the company in the US, following its focus on Specialty business.

On a consolidated basis, Industries' net profit rose 117.3% to Rs 2235.14 crore on 13.2% growth in net sales to Rs 7764.03 crore in Q2 September 2016 over Q2 September 2015.

Industries is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard